According to senior author, Dr Robert Nam (Odette Cancer Centre, Sunnybrook Research Institute, University of Toronto, Canada):
“In the past, studies that have compared the success rates of surgery or radiation have been confusing because of their methods. We have evaluated all the good-quality data comparing surgery and radiotherapy, and the results are pretty conclusive; in general, surgery results in better mortality rates than radiotherapy. Nevertheless, there are times when radiotherapy may be more appropriate than surgery, so it is important that a patient discusses treatment options with his clinician.”
Localised prostate cancer — where the cancer is confined to the prostate — accounts for around 80% of prostate cancers. Around 400,000 men are diagnosed with prostate cancer each year in Europe, meaning that around 320,000 will suffer from localised prostate cancer2. The most common way of treating localised prostate cancers are either with radiotherapy, or with surgery. The choice of radiotherapy or surgery varies according to country. For example, in England and Wales, radiotherapy is used more often than surgery3.
The researchers conducted a meta-analysis (a ‘study of studies’) which compared 19 studies including up to 118,830 patients who had undergone treatment with either surgery or radiation.
The analysis had to consider a variety of studies which compared different parameters (such as duration of the study). Fifteen of the studies compared patients who died of prostate cancer after surgery or radiation; they found that over the duration of the studies, patients were twice as likely to die from prostate cancer after being treated with radiation, compared to surgery, (Hazard Ratio 2.08, 95% confidence interval 1.76-2.47, p 0.00001).
Ten of the studies also looked at overall mortality (where the cause of death was not necessarily from prostate cancer), and found that patients treated with radiation were about one and half times more likely to die sooner than patients who had surgery (HR 1.63, 95% confidence interval 1.54-1.73, p 0.00001)
“Both treatment approaches should be discussed with patients prior to the start of therapy,” says Dr Robert Nam, “the important thing about this research is that it gives physicians and patients additional, information to consider when making the decision about how to treat localised prostate cancer.
Commenting Professor Nicolas Mottet (St Étienne, France) Chairman of the European Association of Urology Prostate Guideline Panel said:
“This systematic review suggests that survival is better after surgery compared to various forms of radiotherapy. It deserves attention, as it is based on the best available data. However, definitive proof needs a large well-conducted randomized control trial, such as the upcoming PROTECT trial which is due to report next year. So we certainly need to take this analysis into account, but it doesn’t yet give us a definitive answer as to the best treatment. Although this paper should not change clinical practice, I agree with the authors, this analysis gives us important, additional information.”